Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sangamo Therapeutics
(NQ:
SGMO
)
0.8576
-0.0022 (-0.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
4,726,990
Open
0.8500
Bid (Size)
0.8550 (3)
Ask (Size)
0.8794 (5)
Prev. Close
0.8598
Today's Range
0.8400 - 0.9300
52wk Range
0.2911 - 1.480
Shares Outstanding
145,337,046
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
August 06, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Why Sangamo Therapeutics Stock Is Soaring
August 06, 2024
Sangamo Therapeutics shares are trading higher Tuesday after the company announced it has entered into a license agreement with Genentech to develop intravenously administered genomic medicines for...
Via
Benzinga
Performance
YTD
+54.16%
+54.16%
1 Month
+27.62%
+27.62%
3 Month
+38.03%
+38.03%
6 Month
-23.43%
-23.43%
1 Year
+11.36%
+11.36%
More News
Read More
Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?
August 06, 2024
Via
InvestorPlace
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
August 06, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Peering Into Sangamo Therapeutics's Recent Short Interest
July 25, 2024
Via
Benzinga
4 Analysts Assess Sangamo Therapeutics: What You Need To Know
March 13, 2024
Via
Benzinga
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
July 30, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 26, 2024
Via
Benzinga
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?
July 24, 2024
Via
InvestorPlace
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings
July 24, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 24, 2024
Via
Benzinga
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
July 24, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
July 24, 2024
Via
Benzinga
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
July 24, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
July 11, 2024
Via
AB Newswire
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
May 15, 2024
Via
Benzinga
SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
May 09, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
May 09, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
May 02, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 22, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
March 22, 2024
Via
Benzinga
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
March 22, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
March 19, 2024
Via
Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.